Adicet Bio

Notes

Adicet Bio (Nasdaq: ACET) is a clinical-stage biotechnology company focused on developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company's platform leverages "off-the-shelf" gamma delta T cells engineered with chimeric antigen receptors (CARs) to provide durable therapeutic activity.

Adicet's lead program, ADI-001, is a gamma delta CAR T cell therapy targeting CD20, being developed in a basket study across six autoimmune indications including lupus nephritis, systemic lupus erythematosus, systemic sclerosis, idiopathic inflammatory myopathy, stiff person syndrome, and ANCA-associated vasculitis.

In July 2025, the company underwent restructuring, discontinuing its ADI-270 oncology program for renal cell carcinoma to focus primarily on autoimmune diseases. This resulted in a 30% workforce reduction.

The company was formed in 2020 through a reverse merger between resTORbio and privately-held Adicet Bio, with Adicet shareholders owning 75% of the combined entity.

Team

Chen Schor - President & Chief Executive Officer
Blake Aftab, Ph.D. - Chief Scientific Officer
Greg Vosganian, M.D. - Vice President of Clinical Development
Benjamin Hsu, M.D. - Vice President of Clinical Development (Autoimmune)
Ekatherina Goryachikov - Vice President & Head of Clinical Operations

Additional Research Findings

Lead program: ADI-001 (anti-CD20 gamma delta CAR T) in Phase 1 for six autoimmune indications
Discontinued ADI-270 (anti-CD70 for renal cell carcinoma) in July 2025 to focus on autoimmune
ADI-212: gene edited and cytokine-armored candidate targeting PSMA (IND-enabling studies)
Publicly traded on Nasdaq (ticker: ACET) since 2020 merger
Headquarters: Redwood City, CA and Boston, MA
Pioneering use of gamma delta T cells vs. traditional alpha beta T cells for longer durability
30% workforce reduction announced July 2025

Notes

Team

Additional Research Findings

Sources

Investors